Changes in celebrospinal fluid concentration of oxidative stress markers during chemotherapy of acute lyphoblastic leukaemia in children

• Autorzy: Protas P. , Muszynska-Roslan K. , Holownia A. , Krawczuk-Rybak M. , Braszko J.
• Języki publikacji: EN

Abstrakty

EN

In this study we advised question whether cerebrospinal fl uid oxidative stress markers are associated with neurotoxicity of chemotherapy of acute lymphoblastic leukaemia (ALL). Examination of 38 ALL patients revealed a statistically signifi cant increase in 8-isoprostane and decrease in total antioxidative capacity during the treatment. Dynamic analysis revealed a statistically signifi cant increase in isoprostane starting on the 59th day of the treatment when the levels were highest and remained raised during all the treatment course. The mean 8-isoprostane level at the diagnosis was 9.05 ± 5.12 pg/ml, and no correlation with initial leukocytosis, organomegaly and lactate dehydrogenase level was noted. Dynamic data analysis revealed a statistically signifi cant increase in 8-isoprostane on the 59th day of the treatment (24.85 ± 26.28) and at four points during consolidation phase (17.28 ± 8.09; 22.72 ± 21.79; 24.92 ± 22.74; 32.32 ± 26.85) as compared to its level at the diagnosis (P<0.01. The mean total antioxidative capacity level at the diagnosis was (203.98 ± 15.11 μmol/l). Dynamic data analysis revealed a statistically signifi cant decrease in total antioxidative capacity on the 59th day of the treatment (189.76 ± 4.64) and at one point during consolidation phase (188.29 ± 8.46) as compared to its level at the diagnosis (P<0.05). The study suggests that standard ALL treatment may cause neurotoxicity by oxidative stress.

• Wydawca: -
• Czasopismo: Acta Neurobiologiae Experimentalis
• Rocznik: 2009
• Tom: 69
• Numer: 3
• Opis fizyczny: p.318

Twórcy

autor

Protas P.

• Department of Clinical Pharmacology, Medical University of Bialystok, Bialystok, Poland

autor

Muszynska-Roslan K.

• Department of Pediatric Oncology, Medical University of Bialystok, Bialystok, Poland

autor

Holownia A.

• Department of Clinical Pharmacology, Medical University of Bialystok, Bialystok, Poland

autor

Krawczuk-Rybak M.

• Department of Pediatric Oncology, Medical University of Bialystok, Bialystok, Poland

autor

Braszko J.

• Department of Clinical Pharmacology, Medical University of Bialystok, Bialystok, Poland